The Australian medical sector is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in early trials for addressing obesity. This treatment https://bookmarkahref.com/story21754678/retatrutide-australia-a-potential-hope-for-weight-loss